Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG
Van der Werff Ten Bosch, J; Suciu, S; Thyss, Aet al.
[en] Between November 1990 and November 1996, EORTC Children Leukemia Group conducted a randomized trial in de novo acute lymphoblastic leukemia and lymphoblastic non-Hodgkin’s lymphoma patients using a Berlin–Frankfurt–Munster protocol to evaluate the monthly addition of intravenous 6-mercaptopurine (i.v. 6-MP) (1 g/m2) to conventional continuation therapy comprising per oral MTX weekly and 6-MP daily. Only during the first 18 months of the randomization period, 6-MP p.o. was interrupted for 1 week after each i.v. 6-MP. A total of 877
patients was randomized to either no i.v. 6-MP (Arm A) or additional i.v. 6-MP (Arm B). A total of 217 relapses (91 in Group A vs 128 in Group B) and 13 deaths in CR (5 vs 8) were reported; a total of 134 patients (55 vs 79) died. The median follow-up was 7.6 years. At 8 years, the disease-free survival rate was lower (P¼0.005) in Arm B (69.1% (s.e.¼2.2%)) than in Arm A (77.9% (s.e.¼2.0%)), and the hazard ratio was 1.45 (95% CI 1.12–1.89).
In conclusion, as delivered in this study, i.v. 6-MP was detrimental to event-free survival.
Disciplines :
Hematology Pediatrics Oncology
Author, co-author :
Van der Werff Ten Bosch, J
Suciu, S
Thyss, A
Bertrand, Y
Norton, L
Mazingue, F
Uyttebroeck, A
Robert, A
Boutard, P
Ferster, A
Plouvier, E
Maes, P
Munzer, M
Plantaz, D
DRESSE, Marie-Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Service de pédiatrie (CHR)
Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Pinkel D. Five-year follow-up of 'total therapy' of childhood lymphocytic leukemia. JAMA 1971; 216: 648-652.
Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-615.
Riehm H, Feickert H, Lampert F. Cancer in children. Clinical Management. Berlin: Springer, 1986.
Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983; 308: 1005-1009.
Estlin EJ, Lowis SP, Hall AG. Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 110: 29-40.
Camitta B, Leventhal B, Lauer S, Shuster JJ, Adair S, Casper J et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 1989; 7: 1539-1544.
Camitta B, Mahoney D, Leventhal B, Lauer SJ, Shuster JJ, Adair S et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 1994; 12: 1383-1389.
Jacqz-Aigrain E, Nafa S, Medard Y, Bessa E, Lescoeur B, Vilmer E. Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia. Eur J Clin Pharmacol 1997; 53: 71-74.
Covell DG, Narang PK, Poplack DG. Kinetic model for disposition of 6-mercaptopurine in monkey plasma and cerebrospinal fluid. Am J Physiol 1985; 248: R147-R156.
Zimm S, Ettinger L, Holcenberg J, Kasen B, Vietti T, Belasco J et al. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 1985; 45: 1869-1873.
Adamson PC, Zimm S, Ragab AH, Steinberg SM, Balis F, Kamen BA et al. A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol 1990; 26: 343-344.
Duval M, Suciu S, Lutz P, Benoit Y, Robert A, Thyss A et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002; 99: 2734-2739.
Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A et al. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 2001; 19: 1935-1942.
Langermann H, Henze G, Wulf M, Rhiem H. Abschatzung der tumorzellmasse bei der akuten lymphoblastischen leukamie im kindesalter: prognotische bedeutung- und praktische anwendung. Klin Ped 1982; 194: 209-213.
Murphy S. Classification, staging and end results of treatment in childhood non-Hodgkin's lymphoma: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7: 332-339.
Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991; 78: 1166-1172.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
Harris NL, Jaffe ES, Stein H, Banks PM, Chart JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
Linder J, Ye Y, Armitage JO, Weisenburger DD. Monoclonal antibodies marking B-cell non-Hodgkin's lymphoma in paraffin-embedded tissue. Mod Pathol 1988; 1: 29-34.
Group FMCS. Morphologic, immunologic, and cytogenetic (MIC) working classification of acute lymphoblastic leukemias. Report of the workshop held in Leuven, Belgium, April 22-23, 1985. First MIC Cooperative Study Group. Cancer Genet Cytogenet 1986; 23: 189-197.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000; 14: 2257-2266.
Buyse M, Staquet M, Sylvester R. Cancer Clinical Trials: Methods and Practice. Oxford, England: Oxford Medical Publication, 1984.
Cox D, Oakes D. Analysis of Survival Data. New York: Chapman & Hall, 1984.
Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000; 14: 2247-2256.
Bostrom B, Sensel M, Sather H, Gaynon P, La M, Johnston K et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101: 3809-3817.
Mahoney Jr DH, Shuster JJ, Nitschke R, Lauer S, Steuber CP, Camitta B. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 2000; 18: 1285-1294.
Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002; 16: 1099-1111.
Elion GB. The purine path to chemotherapy. Science 1989; 244: 41-47.
Schmiegelow K, Bjork OG, Glomstein A, Gustafsson G, Keiding N, Kristinsson J et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 1332-1339.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.